Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden (IMPROWE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03976557
Recruitment Status : Terminated (Due to Corona/Covid19 pandemic)
First Posted : June 6, 2019
Last Update Posted : January 22, 2021
Sponsor:
Collaborator:
Danderyd Hospital
Information provided by (Responsible Party):
Bactiguard AB

Brief Summary:

Primary objective of the study is to establish the incidence of all any catheter related complications in BIP CVC and standard CVC groups in patients requiring CVC.

(CVC - Central Venous Catheter; BIP - Bactiguard Infection Protection)


Condition or disease Intervention/treatment Phase
Vascular Access Complication Catheter-Related Infections Catheter Thrombosis Catheter Blockage Catheter Complications Catheter Site Discomfort Catheter Bacteraemia Device: BIP CVC Device: Standard CVC Not Applicable

Detailed Description:

Catheter related complications include CRBSI, CRI, Local CVC infection, need to exchange of CVC due to suspected CRI/CRBSI or thrombosis, stop / slower flow in any CVC lumen, local thrombosis, device malfunctions / technical catheter problems, device related adverse events.

(CRBSI - Catheter Related Blood Stream Infection; CRI - Catheter Related Infection)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Pilot, randomized, open label, controlled trial
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Implementation and Evaluation of BIP CVC in Access Center at Danderyd Hospital, Stockholm, Sweden. Study Protocol
Actual Study Start Date : April 11, 2019
Actual Primary Completion Date : December 18, 2019
Actual Study Completion Date : December 18, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BIP CVC
Polyurethane CVC with noble metal coating
Device: BIP CVC
Central venous access with noble metal coated CVC
Other Name: Noble metal coated CVC

Active Comparator: Standard CVC
Standard CVC made of polyurethane
Device: Standard CVC
Central venous access with standard uncoated CVC
Other Name: Uncoated CVC




Primary Outcome Measures :
  1. Number of patients with catheter related complications [ Time Frame: From CVC insertion until CVC withdrawal ]
    Patients having any complication specified as secondary endpoints


Secondary Outcome Measures :
  1. Number of patients with CRBSI [ Time Frame: From CVC insertion until CVC withdrawal ]
    CRBSI - Catheter Related Blood Stream Infections

  2. Number of patients with CRI [ Time Frame: From CVC insertion until CVC withdrawal ]
    CRI - Catheter Related Infections

  3. Number of patients with local CVC infections [ Time Frame: From CVC insertion until CVC withdrawal ]
    Skin infection at the insertion site

  4. Number of CVC exchanges per patient due to suspected infection or thrombosis [ Time Frame: From CVC insertion until CVC withdrawal ]
    Reported as incidence

  5. Number of patients with stop or slower flow in any CVC lumen [ Time Frame: From CVC insertion until CVC withdrawal ]
    Stop or slower flow or need of high pressure during blood sample withdrawal and/or injection of solution

  6. Number of patients with local thrombosis [ Time Frame: From CVC insertion until CVC withdrawal ]
    Local thrombosis - thrombosis in the insertion vein

  7. Number of patients with device malfunctions [ Time Frame: From CVC insertion until CVC withdrawal ]
    Any device malfunction or technical problems during insertion, withdrawal or use

  8. Number of patients with antibiotics and antithrombotics drug use [ Time Frame: From CVC insertion until CVC withdrawal ]
    including the reason of use and dose / number of days

  9. Number of patients with adverse events [ Time Frame: From CVC insertion until CVC withdrawal ]
    including casuality assessment to the CVC use; both serious and non-serious



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients admitted to the Access Center at Danderyd who need an elective CVC (surgery, infection, nutrition, medication…)
  2. Fully recognize and understand patient information
  3. Signed informed consent

Exclusion Criteria:

  1. If CVC present prior to inclusion in the study and no intention to change the present CVC over guidewire
  2. Age < 18 years
  3. Pregnant women
  4. Known allergy to gold, silver and palladium
  5. Participation in other clinical studies which may interfere with this study as judged by the Investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03976557


Locations
Layout table for location information
Sweden
Danderyd Sjukhus
Stockholm, Sweden, 18288
Sponsors and Collaborators
Bactiguard AB
Danderyd Hospital
Investigators
Layout table for investigator information
Principal Investigator: Jan Jakobsson, Prof Danderyd Hospital
Layout table for additonal information
Responsible Party: Bactiguard AB
ClinicalTrials.gov Identifier: NCT03976557    
Other Study ID Numbers: PL-13732
First Posted: June 6, 2019    Key Record Dates
Last Update Posted: January 22, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacteremia
Catheter-Related Infections
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Bacterial Infections
Sepsis
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes